Salarius Pharmaceuticals - AI Stock Analysis

Analysis generated December 22, 2025

Salarius Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for rare and pediatric cancers as well as other difficult-to-treat indications. The company's primary focus is on epigenetic-based therapies, which target the underlying mechanisms driving cancer and other diseases. Salarius is dedicated to advancing its pipeline of drug candidates through clinical trials with the aim of providing innovative solutions to patients in need.

Fundamental Analysis

Salarius Pharmaceuticals reported no revenue for the last quarter. While at first glance, this may raise concerns, the consistency in revenue over the past year indicates a stable foundation as the company remains in the clinical stage, prioritizing research and development over immediate revenue generation.

The net income for the last quarter was $870,000, an increase of 8.81% compared to the previous quarter and a 10.15% increase compared to the same quarter last year. This positive growth both sequentially and year-over-year suggests effective cost management and operational efficiency improvements.

EBITDA for the last quarter was also $870,000. This represents a 9.55% increase compared to the previous quarter and a 13.23% increase compared to the same quarter last year, indicating strong financial health and an upward trajectory in operational performance.

Technical Analysis

The current stock price of Salarius Pharmaceuticals is $0.67, a substantial decrease of 22.99% compared to a month ago and a striking 97.15% decrease compared to a year ago. These statistics may present a concern for investors considering the significant depreciation in value over both the short and long terms.

Further technical indicators show a bearish trend. The current SMA10 is $0.71, slightly lower than the previous SMA10 of $0.72, suggesting a potential continuation of the downward trend in price movement. With the Relative Strength Index (RSI) at 61.9, the stock stands at a neutral level, indicating neither overbought nor oversold conditions at this moment.

Alternative Data Analysis

Alternative data provides additional insights beyond traditional financial metrics. Starting with job postings, Salarius Pharmaceuticals has 0 open positions, confirming a stable workforce. Moreover, employee sentiment is exceptionally high, with an estimated 100% of employees having a positive outlook, a strong indicator of internal confidence and morale.

On the customer acquisition front, the company’s website has seen an estimate of 4,000 visitors, an increase of 33% over the last couple of months. This uptick in website traffic may indicate rising interest in the company's offerings, which is a bullish signal.

Lastly, AltIndex’s AI score for Salarius Pharmaceuticals is 59, which translates to a hold signal. This score is derived from a comprehensive analysis of fundamental, technical, and alternative data, suggesting that the stock's current performance does not strongly lean towards either buying or selling.

Conclusion and Recommendation

Based on the extensive analysis, Salarius Pharmaceuticals appears to be demonstrating operational and financial growth despite no revenue generation as expected from its clinical-stage status. The technical analysis reveals a bleak short and long-term stock price performance but does not flag significant risk based on the neutral RSI. Alternative data analysis yields positive insights regarding employee sentiment and customer acquisition trends, enhancing the company’s prospects.

Considering the combination of fundamental strengths and current technical pressures, it is recommended to hold the stock and monitor further developments particularly in clinical advancements and potential revenue generation. Continuous growth in net income and EBITDA, coupled with positive trends in alternative data, may offer potential upside in the medium to long term.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.